Correction: Bertuzzi et al. Microenvironmental Traits of Classical Hodgkin’s Lymphoma in Adolescents and Their Prognostic Impact. Cancers 2024, 16, 4210
Clara Bertuzzi(Azienda USL di Bologna), Elena Sabattini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Massimo Mascolo(University of Naples Federico II), Giulia Gabrielli(Hospital of the University of Pennsylvania), Maura Rossi(University of Bologna), Arcangelo Prete(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Matteo Carella(Istituto di Ematologia di Bologna), Simona Righi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Elena Facchini(Azienda USL di Bologna), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Maurizio Baldassarre(Azienda USL di Bologna), Claudio Agostinelli, Giovanna Motta(Azienda USL di Bologna)
Cited by 0
Related Papers
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523